



U.S. Department of Justice

Andrew E. Lelling
United States Attorney
District of Massachusetts

Main Reception: (617) 748-3100

John Joseph Monkley United States Courthouse
1 Courthouse Way
Suite 9200
Boston, Massachusetts 02210

December 4, 2018

Sheriff Kevin F. Coppinger
Essex County Sheriff's Department
20 Manning Ave
P.O. Box 807
Middleton, Massachusetts 01949-2807

Dear Sheriff Coppinger:

Thank you for meeting with us on November 8 to discuss our inquiry into the provision of Medication Assisted Treatment in your facilities and the Americans with Disabilities Act (ADA). I want to reiterate that we see this as a collaborative process and appreciate your willingness to work together toward addressing this important issue. As I indicated, my office can be a resource to provide support in helping you achieve ADA compliance, which based on our discussion is a goal we both share.

In the interest of collaboration, please set aside for the moment our pending request for documents. We instead look forward to starting work with you to find a collaborative solution to this issue that achieves compliance but also recognizes the legitimate concerns of correctional administrators.

Again, thank you for your interest in collaboration, and we looking to forward to working with you.

Sincerely,

A handwritten signature in blue ink, appearing to read "A. Lelling", is written over a horizontal line.

Andrew E. Lelling
United States Attorney



Essex County Sheriff's Department

20 Manning Ave
P.O. Box 807
Middleton, MA 01949-2807



Kevin F. Coppinger
Sheriff

Telephone 978-750-1900
www.essexsheriffma.org

November 21, 2018

United States Attorney Andrew Lelling
U. S. Federal Courthouse
1 Courthouse Way, Suite 9200
Boston, Massachusetts 02210

Dear Mr. Lelling,

I would like to once again thank you for taking time out of your busy schedule to meet with me and our Chief of Staff Dennis Newman on November 8 to discuss the issues of Medically Assisted Treatment (MAT) in our correctional facilities here in Essex County and beyond. Since the concept of full MAT in our facilities is still in its infancy stage, I was encouraged by your willingness to work with us in a collaborative effort to help develop best practices for the proper care of the inmates in need of treatment while addressing the operational, safety and security concerns of our facilities in general.

In regard to your agency's letter dated October 9, 2018, it is my understanding that we are going to set that aside while we work collaboratively towards the above stated goal. Our department looks forward to working with you on such an important topic.


Thank you again for your time and cooperation.

Respectfully,

Kevin F. Coppinger
Sheriff

Proudly serving the communities of Essex County

AMESBURY • ANDOVER • BEVERLY • BOXFORD • DANVERS • ESSEX • GEORGETOWN • GLOUCESTER • GROVELAND
HAMILTON • HAVERHILL • IPSWICH • LAWRENCE • LYNN • LYNNFIELD • MANCHESTER-BY-THE-SEA • MARBLEHEAD
MERRIMAC • METHUEN • MIDDLETON • NAHANT • NEWBURY • NEWBURYPORT • NORTH ANDOVER • PEABODY
ROCKPORT • ROWLEY • SALEM • SALISBURY • SAUGUS • SWAMPSCOTT • TOPSFIELD • WENHAM • WEST NEWBURY



Department of Justice
United States Attorney's Office
John Joseph Moakley United States Courthouse
1 Courthouse Way
Suite 9200
Boston, Massachusetts 02210
Main Reception: (617) 748-3100

Andrew E. Lelling
United States Attorney
District of Massachusetts



Facsimile Transmission Cover Page

SENSITIVE U.S. ATTORNEY FAX TRANSMISSION			
The information contained in this facsimile message and any and all attachments thereto is confidential, sensitive, or otherwise exempt from public release under the Freedom of Information Act. It is to be controlled, stored, handled, transmitted, and disposed of in accordance with the policies and procedures of the U.S. Department of Justice. It is to be protected from unauthorized disclosure and its use is limited to official business purposes only. It is to be destroyed when no longer needed for official business purposes. It is to be disposed of in accordance with the policies and procedures of the U.S. Department of Justice. It is to be stored, handled, transmitted, and disposed of in accordance with the policies and procedures of the U.S. Department of Justice. It is to be protected from unauthorized disclosure and its use is limited to official business purposes only. It is to be destroyed when no longer needed for official business purposes. It is to be disposed of in accordance with the policies and procedures of the U.S. Department of Justice.			
RECIPIENT		SENDER	
To:	Attorney Richard Jeffrey	From:	Gregory Dorchak, SAUSA
Fax#:	978-750-1999	Fax#:	617-748-3971
Phone#:		Phone#:	617-748-3157
CC:			
Total Number of Pages (including Cover Page)			
5		Date: 10/22/2018	

☐ Urgent☒ For Review☐ Please Comment☐ Please Reply

IMMEDIATELY NOTIFY SENDER OF ANY DIFFICULTIES IN TRANSMISSION

Comments/Information:



U.S. Department of Justice

Andrew E. Lelling
United States Attorney
District of Massachusetts

Main Reception: (617) 748-3100

John Joseph Monkley United States Courthouse
1 Courthouse Way
Suite 9200
Boston, Massachusetts 02210

October 9, 2018

Via First Class Mail

Attorney Richard Jeffery
Essex County Sheriff's Department
20 Manning Ave.
Middleton, MA 01949

Re: Investigation of the Essex County Sheriff's Department Pursuant to the
Americans with Disabilities Act

Dear Attorney Jeffery:

We are writing to inform you that the U.S. Attorney's Office for the District of Massachusetts has initiated an investigation of the Essex County Sheriff's Department ("the Department") for compliance with the requirements of Title II of the Americans with Disabilities Act of 1990 (ADA), 42 U.S.C. §§ 12131-12165, and its implementing regulations, 28 C.F.R. part 35. These ADA regulations may be found at www.ADA.gov.

Specifically, this investigation focuses on the provision of services for individuals with Opioid Use Disorder (OUD) whose disability, prior to confinement, has been identified as requiring Opioid-Agonist Treatment (OAT) for treatment.¹ Individuals in treatment for OUD are protected by the ADA. It has come to our attention that individuals in treatment for OUD entering the Department's facilities, who are being treated with OAT, are not allowed access to OAT while in custody.

We ask that you provide the following information within thirty (30) calendar days of the date of this letter. If any of the information requested is not available in writing, please provide corresponding documents, written policies, or other written material that addresses the substance of the information requested. This request falls within DOJ's federal law enforcement authority. Such authority creates exceptions to statutes that may otherwise limit disclosure of private information, including the Health Insurance Portability and Accountability Act of 1996

¹ OAT includes methadone and buprenorphine, which is most commonly found in the drugs Suboxone and Subutex.



("HIPAA"), Public Law 104-191.²

INFORMATION REQUESTED

1. Provide a list of all facilities licensed, funded, or operated by the Department. For each facility, list the facility's capacity and current number of inmates and detainees;
2. Provide a list of all vendors who provide health services or substance use treatment services for the Department, including all vendors who are under contract but who have not yet begun providing services, with a description of services provided by each vendor, as well as what facilities those vendors operate within. Please include all contracts with said vendors;
3. Provide a description of any needs assessment used to determine if any individual is in need of substance use treatment services;
4. Provide a description of all substance use treatment programs used within the Department's facilities, including a description of program philosophy and goals, overview of program rules, and of participant responsibilities, and including program manual. If the program is provided by a vendor, provide the name of vendor used;
5. Provide a description of any steps used by staff to manage detoxification for individuals who had been prescribed methadone or medications containing buprenorphine prior to confinement;
6. Provide a description of intake procedures, including initial medical evaluations. Please include any blank forms used during these procedures;
7. Provide a description of the various security methods used to administer medication (such as via pill lines). Please explain the criteria used to determine which medications are administered using a particular method;
8. Provide a description of how staff determine which medications are maintained for newly detained individuals. Please include the title of the individual who performs this evaluation;
9. Provide a description of the pharmacy services available at each facility;
10. Provide a list of all medications—including, but not limited to methadone and medications containing buprenorphine—that are terminated upon intake, and, when

² HIPAA does not limit the Commonwealth's ability to disclose the requested information to the Department in these circumstances. See 45 C.F.R. § 164.512(d); *United States ex rel. Kaplan v. Metro. Ambulance & First-Aid Corp.*, 395 F. Supp. 2d 1, 4 (E.D.N.Y. 2005) (stating that "The United States Department of Justice is a health oversight agency as defined in" HIPAA).

relevant, what alternative medications are provided;

11. Provide the names of the superintendent at each facility;
12. Provide the names of all medical personnel and clinicians, including vendors, and including any and all certifications of individuals authorized to prescribe medication. For any medical doctor, please include the doctor's specialty;
13. Provide any reports or evaluations associated with opioid use treatment programs generated within the past three years;
14. Provide copies of all training materials provided to staff concerning any opioid use treatment programs put in place at each facility;
15. Provide all policies and procedures for handling individuals with opioid use disorder, including those of any contractual medical provider;
16. Provide all policies and defined procedures for the clinical management of chemical dependent inmates, including those policies that address treatment and observation of inmates manifesting mild/moderate symptoms of withdrawal, and including those of any contractual medical provider;
17. Provide a copy of the pharmaceutical formulary used at each facility;
18. Provide a copy of all intake records for all inmates or detainees, where the inmate had disclosed that they were prescribed either methadone or medications containing buprenorphine, from the previous three years. Please ensure that this includes the booking number, name and aliases, current address, date and duration of confinement, substance use history, date of birth, and social security number;
19. Provide a copy of each monthly report prepared for the Commissioner of Corrections that lists all admissions and releases, for the past three years;
20. Provide a copy of any grant application, made to any entity, which was made for the purpose of funding any substance use program at the Department. If the grant was accepted, please include any subsequent grant documents.
21. Provide the number of contraband offenses occurring within each facility for the last three years that involved medications and illegal drugs, broken down by medication or drug and by month.
22. Provide, as a spreadsheet, a list of all inmates or detainees released from custody for the past three years. Please include first name, last name, social security, date of birth, and date of release.

Please provide electronically stored information and documents in their native format

(e.g., Microsoft Word file, Microsoft Excel file, PDF file). To the extent that information or documents are stored in a non-electronic format, please contact us to make arrangements for a usable transfer of the data.

We drafted our request with the goal of reducing your production burden while remaining firmly within the contours of investigative needs. If we have made a request that needs clarification, or if you think that there is a better alternative, please do not hesitate to let us know.

Although we believe it is appropriate to begin an investigation in light of the above-referenced information, we have not reached any conclusions about whether the ADA has been violated. As we commence our investigation, we will consider all relevant information, and we invite your full cooperation in identifying that information. We will seek to minimize any potential disruptions of normal operations during our investigation.

The attorneys handling this investigation are Civil Rights Unit Chief Jennifer Serafyn (617-748-3188) and Special Assistant U.S. Attorney Gregory Dorchak (617-748-3157). Please do not hesitate to contact us if you have any questions in the interim.

Sincerely,

Andrew E. Lelling
United States Attorney

By:

/s/ Gregory J. Dorchak
Jennifer A. Serafyn
Chief
Gregory J. Dorchak
Special Assistant U.S. Attorney
Civil Rights Unit